The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian public Healthcare system and Health policy to ensure affordable drugs for all. Studies show that as much as 70% of Health spending in India comes from out-of-pocket payments, with 50-80% of...

-The Hindu     Enhancing the basket of contraceptive choices can reduce maternal mortality rate, says a family planning review Family planning has made a silent comeback in the national discourses. This time, focussing more on concomitant improvement in the Health of the people rather than limiting the number of children. India had changed its strategy on family planning in 2010 with the other developing countries from that of merely reducing population to that of...

-The Telegraph About half of Delhi's police personnel are overweight and have high blood pressure or cholesterol, heart problems, diabetes, insomnia or weak eyesight, a Health camp has found out. Senior officers declined comment but their juniors, requesting anonymity, blamed overwork and stress. An internal police report says that 48 per cent among the 2,000 who participated in the 19-day camp were overweight and had high cholesterol. Over a third - 34 per...

-The Hindu Concerned over the extreme left groups' penetration into tribal territories and their ability to win over the hearts and minds of people deprived of basic necessities of life, the government has drawn-up a nine point action plan to deal with a host of development challenges. The action plan is an outcome of series of meeting of a specially constituted Review Group of LWE (Left-Wing Extremism) under the aegis of...

-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...